【佳学基因检测】乳酸：免疫微环境的调节剂和结直肠癌的临床预后指标

中国dota2吧雷电竞 基因检测公司排名详解

讨论肿瘤个性化药物研究路径做了备注，备注表明《Front Immunol》在. 2022 Aug 26;13:876195.发表了一篇题目为《乳酸：免疫微环境的调节剂和结直肠癌的临床预后指标》肿瘤dota2吧雷电竞 治疗基因检测临床研究文章。该研究由Daoqi Zhu, Yiping Jiang, Huihui Cao, Jiabin Yang, Yuqi Shu, Haowei Feng, Xiaoyu Yang, Xiaomin Sun, Meng Shao等完成。促进了肿瘤的正确治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及正确治疗临床研究内容关键词：

结直肠癌,免疫疗法,乳酸评分,微环境,预后模型

肿瘤靶向治疗基因检测临床应用结果

乳酸可在肿瘤微环境中发挥免疫抑制作用，通过募集和诱导免疫抑制细胞和分子的活性来促进肿瘤的发展。高乳酸浓度对于肿瘤细胞转移、血管生成和治疗抗性很重要。随着对肿瘤代谢研究的深入，参与糖酵解的关键因素之一乳酸越来越多地显现出其在结直肠癌（CRC）中的特征性临床价值。在肿瘤微环境调节基因与肿瘤治预后的基因检测的开发中，基于乳酸代谢途径筛选乳酸基因。随后，通过对包括免疫检查点、免疫浸润和临床特征在内的各级亚型的基因进行聚类和分析，确定了乳酸亚型，揭示了乳酸代谢在结直肠癌中的生物学意义。基于亚型的差异基因分析得出乳酸评分，可对结直肠癌的预后进行分层。肿瘤微环境基因解码基因检测发现27个乳酸基因和61个乳酸表型基因与免疫细胞浸润相关，并具有显着的预后功效。基于乳酸基因和乳酸表型基因检测结果，结直肠癌患者被分为四个亚型和五个集群。在这些亚型和集群中，标志性途径（即免疫相关特征和趋化因子）的存活时间和活动存在显着差异。特别是，簇 2 和亚型 1 的乳酸评分显着高于其他亚型。综上所述，乳酸基因检测评分是dota2吧雷电竞 的独立预后因素，可作为预测结直肠癌进展的临床指南，并可作为结直肠癌免疫治疗效果的评价因素。免疫疗法；乳酸评分；微环境；预后模型。

肿瘤发生与反复转移国际数据库描述：

Lactate can play an immunosuppressive role in the tumor microenvironment and promote tumor development by recruiting and inducing the activity of immunosuppressive cells and molecules. High lactate concentrations are important for tumor cell metastasis, angiogenesis, and treatment resistance. With the in-depth studies on tumor metabolism, lactate, one of the key factors involved in glycolysis, has been increasing emerged its characteristic clinical value in colorectal cancer (CRC). In this study, lactate genes were screened based on lactate metabolism pathways. Subsequently, the lactate subtypes were determined by clustering and analysis of the subtypes at all levels, including immune checkpoints, immune infiltration, and clinical characteristics, which revealed the biological significance of lactate metabolism in CRC. Subtype-based differential gene analysis resulted in a lactate score, which stratifies the prognosis of CRC. We discovered that 27 lactate genes and 61 lactate-phenotype genes are associated with immune cell infiltration and have a significant prognostic efficacy. The CRC patients were clustered into four subtypes and five clusters, based on lactate genes and lactate-phenotype genes, respectively. There are significant differences in survival time and activities of hallmark pathways, namely immune-related signatures and chemokines, among these subtypes and clusters. Particularly, cluster 2 and subtype 1 have significantly higher lactate scores than that of the others. In conclusion, lactate score is an independent prognostic factor for cancer that can be used as a clinical guide for predicting CRC progression and as an evaluation factor for the effect of immunotherapy in CRC.Keywords: colorectal cancer; immunotherapy; lactate score; microenvironment; prognostic model.